Overview Dividends

(MD) Mednax - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US58502B1061

Neonatology, Maternal-Fetal, Pediatric, Hospitalist, Surgery

EPS (Earnings per Share)

EPS (Earnings per Share) of MD over the last years for every Quarter: "2020-09": 0.37, "2020-12": 0.25, "2021-03": 0.24, "2021-06": 0.41, "2021-09": 0.46, "2021-12": 0.52, "2022-03": 0.33, "2022-06": 0.47, "2022-09": 0.4, "2022-12": 0.47, "2023-03": 0.23, "2023-06": 0.39, "2023-09": 0.32, "2023-12": 0.32, "2024-03": 0.2, "2024-06": 0.34, "2024-09": 0.44, "2024-12": 0.51, "2025-03": 0.2427, "2025-06": 0.53, "2025-09": 0.67,
EPS Growth (3y CAGR): 13.76%
EPS Trend (3y Corr): 40.6%
Last SUE: 2.88σ
Qual. Beats: 2

Revenue

Revenue of MD over the last years for every Quarter: 2020-09: 460.635, 2020-12: 416.63, 2021-03: 446.753, 2021-06: 472.959, 2021-09: 492.949, 2021-12: 498.53, 2022-03: 482.229, 2022-06: 486.033, 2022-09: 489.915, 2022-12: 513.844, 2023-03: 491.008, 2023-06: 500.577, 2023-09: 506.612, 2023-12: 496.443, 2024-03: 495.101, 2024-06: 504.296, 2024-09: 511.158, 2024-12: 502.364, 2025-03: 458.359, 2025-06: 468.844, 2025-09: 492.875,
Revenue Growth (3y CAGR): -1.50%
Revenue Trend (3y Corr): -53.1%
Last SUE: 1.25σ
Qual. Beats: 1
Risk via 10d forecast
Volatility 47.1%
Value at Risk 5%th 64.9%
Relative Tail Risk -16.14%
Reward TTM
Sharpe Ratio 1.12
Alpha 44.79
Character TTM
Hurst Exponent 0.470
Beta 0.782
Beta Downside 0.964
Drawdowns 3y
Max DD 59.49%
Mean DD 24.14%
Median DD 19.12%

Description: MD Mednax November 16, 2025

Pediatrix Medical Group, Inc. (formerly MEDNAX) delivers a spectrum of pediatric and perinatal services across U.S. hospitals, including NICU care for premature or high-risk newborns, maternal-fetal medicine for expectant mothers, and broader pediatric subspecialties such as intensive care, surgery, and emergency medicine. Its clinical model relies on physician subspecialists, nurse practitioners, and allied health professionals who operate within neonatal units, labor-and-delivery suites, and pediatric departments.

In FY 2023 the company reported roughly $2.3 billion in revenue with an adjusted EBITDA margin near 7 %, reflecting steady demand for high-complexity neonatal services. Volume growth in NICU admissions has averaged 4 % YoY, driven by a modest rise in U.S. preterm birth rates (≈10 % of all births) and increasing referral patterns to specialized centers. A key economic driver is the payer mix: about 55 % of revenue comes from Medicare/Medicaid, making the business sensitive to policy changes in reimbursement rates and bundled-payment initiatives targeting perinatal care.

For a deeper, data-rich perspective on MD’s valuation dynamics, you may find ValueRay’s analytical tools helpful.

MD Stock Overview

Market Cap in USD 1,988m
Sub-Industry Health Care Services
IPO / Inception 1995-09-19
Return 12m vs S&P 500 39.7%
Analyst Rating 3.75 of 5

MD Dividends

Currently no dividends paid

MD Growth Ratios

Metric Value
CAGR 3y 13.96%
CAGR/Max DD Calmar Ratio 0.23
CAGR/Mean DD Pain Ratio 0.58
Current Volume 1123.8k
Average Volume 861.7k

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income (162.2m TTM) > 0 and > 6% of Revenue (6% = 115.3m TTM)
FCFTA 0.12 (>2.0%) and ΔFCFTA 6.88pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 16.89% (prev 7.73%; Δ 9.16pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.13 (>3.0%) and CFO 290.0m > Net Income 162.2m (YES >=105%, WARN >=100%)
Net Debt (302.2m) to EBITDA (258.3m) ratio: 1.17 <= 3.0 (WARN <= 3.5)
Current Ratio 1.83 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (85.6m) change vs 12m ago 1.29% (target <= -2.0% for YES)
Gross Margin 25.81% (prev 21.27%; Δ 4.54pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 89.91% (prev 96.64%; Δ -6.72pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 7.57 (EBITDA TTM 258.3m / Interest Expense TTM 31.1m) >= 6 (WARN >= 3)

Altman Z'' 1.44

(A) 0.15 = (Total Current Assets 717.2m - Total Current Liabilities 392.5m) / Total Assets 2.20b
(B) -0.05 = Retained Earnings (Balance) -116.8m / Total Assets 2.20b
(C) 0.11 = EBIT TTM 235.2m / Avg Total Assets 2.14b
(D) -0.09 = Book Value of Equity -115.5m / Total Liabilities 1.31b
Total Rating: 1.44 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 72.30

1. Piotroski 7.0pt = 2.0
2. FCF Yield 12.61% = 5.0
3. FCF Margin 14.22% = 3.56
4. Debt/Equity 0.72 = 2.25
5. Debt/Ebitda 1.17 = 1.52
6. ROIC - WACC (= 6.63)% = 8.29
7. RoE 19.79% = 1.65
8. Rev. Trend -53.13% = -3.98
9. EPS Trend 40.60% = 2.03

What is the price of MD shares?

As of November 19, 2025, the stock is trading at USD 22.96 with a total of 1,123,839 shares traded.
Over the past week, the price has changed by +1.55%, over one month by +36.02%, over three months by +43.50% and over the past year by +58.67%.

Is MD a buy, sell or hold?

Mednax has received a consensus analysts rating of 3.75. Therefor, it is recommend to hold MD.
  • Strong Buy: 3
  • Buy: 0
  • Hold: 5
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the MD price?

Issuer Target Up/Down from current
Wallstreet Target Price 22.7 -1.3%
Analysts Target Price 22.7 -1.3%
ValueRay Target Price 24.8 8.1%

MD Fundamental Data Overview November 17, 2025

Market Cap USD = 1.99b (1.99b USD * 1.0 USD.USD)
P/E Trailing = 12.1204
P/E Forward = 9.6899
P/S = 1.0341
P/B = 2.2321
P/EG = 0.88
Beta = 0.809
Revenue TTM = 1.92b USD
EBIT TTM = 235.2m USD
EBITDA TTM = 258.3m USD
Long Term Debt = 577.2m USD (from longTermDebt, last quarter)
Short Term Debt = 37.6m USD (from shortTermDebt, last quarter)
Debt = 642.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 302.2m USD (from netDebt column, last quarter)
Enterprise Value = 2.17b USD (1.99b + Debt 642.3m - CCE 463.1m)
Interest Coverage Ratio = 7.57 (Ebit TTM 235.2m / Interest Expense TTM 31.1m)
FCF Yield = 12.61% (FCF TTM 273.4m / Enterprise Value 2.17b)
FCF Margin = 14.22% (FCF TTM 273.4m / Revenue TTM 1.92b)
Net Margin = 8.44% (Net Income TTM 162.2m / Revenue TTM 1.92b)
Gross Margin = 25.81% ((Revenue TTM 1.92b - Cost of Revenue TTM 1.43b) / Revenue TTM)
Gross Margin QoQ = 28.48% (prev 26.60%)
Tobins Q-Ratio = 0.99 (Enterprise Value 2.17b / Total Assets 2.20b)
Interest Expense / Debt = 0.48% (Interest Expense 3.06m / Debt 642.3m)
Taxrate = 18.31% (16.1m / 87.8m)
NOPAT = 192.2m (EBIT 235.2m * (1 - 18.31%))
Current Ratio = 1.83 (Total Current Assets 717.2m / Total Current Liabilities 392.5m)
Debt / Equity = 0.72 (Debt 642.3m / totalStockholderEquity, last quarter 890.7m)
Debt / EBITDA = 1.17 (Net Debt 302.2m / EBITDA 258.3m)
Debt / FCF = 1.11 (Net Debt 302.2m / FCF TTM 273.4m)
Total Stockholder Equity = 819.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.37% (Net Income 162.2m / Total Assets 2.20b)
RoE = 19.79% (Net Income TTM 162.2m / Total Stockholder Equity 819.6m)
RoCE = 16.84% (EBIT 235.2m / Capital Employed (Equity 819.6m + L.T.Debt 577.2m))
RoIC = 13.45% (NOPAT 192.2m / Invested Capital 1.43b)
WACC = 6.82% (E(1.99b)/V(2.63b) * Re(8.90%) + D(642.3m)/V(2.63b) * Rd(0.48%) * (1-Tc(0.18)))
Discount Rate = 8.90% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.94%
[DCF Debug] Terminal Value 78.71% ; FCFE base≈210.1m ; Y1≈259.2m ; Y5≈442.2m
Fair Price DCF = 74.57 (DCF Value 6.40b / Shares Outstanding 85.9m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 40.60 | EPS CAGR: 13.76% | SUE: 2.88 | # QB: 2
Revenue Correlation: -53.13 | Revenue CAGR: -1.50% | SUE: 1.25 | # QB: 1

Additional Sources for MD Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle